Last Updated : May 11, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Ledaga | chlormethine hydrochloride | T-cell lymphoma | Do not reimburse | Complete | ||
Piqray | alpelisib | Advanced or Metastatic Breast Cancer | Do not reimburse | Complete | ||
Perjeta | pertuzumab | Early stage breast cancer | Do not reimburse | Complete | ||
MAR-Trientine | Trientine Hydrochloride | Wilson's Disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Abecma | idecabtagene vicleucel | Multiple myeloma | Do not reimburse | Complete | ||
Evenity | romosozumab | Osteoporosis, postmenopausal women | Reimburse with clinical criteria and/or conditions | Complete | ||
Emgality | galcanezumab | Prevention of migraine | Reimburse with clinical criteria and/or conditions | Complete | ||
Opdivo | nivolumab | Esophageal or gastroesophageal junction cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Tagrisso | osimertinib | Non-small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Dojolvi | triheptanoin | Long-chain fatty acid oxidation disorders | Reimburse with clinical criteria and/or conditions | Complete |